What the study of the mutant gene behind aggressive adult leukaemia can offer for treatment

What the study of the mutant gene behind aggressive adult leukaemia can offer for treatment
The U.S.-based multi-institutional study of 830 adult ALL patients treated between 2010 and 2024 found that about one in 10 adults diagnosed with ALL had a mutation in TP53. These patients were more likely to relapse and less likely to survive long-term than those without this genetic mutation